January 29, 2021

results of the Phase III trial for single-shot Janssen COVID-19 Vaccine Candidate

This afternoon, Johnson & Johnson announced top line results from the Company’s global Phase 3 ENSEMBLE trial designed to evaluate the single-shot Janssen COVID-19 vaccine candidate.  The SMC invited Johnson & Johnson’s Vice Chairman of the Executive Committee and Chief Scientific Officer Dr Paul Stoffels, M.D. to brief science journalists about the trial, talk them through the results and answer their questions.  Dr Paul Stoffels was also joined by Moncef Slaoui, Ph.D. – Collaborator on the Trial and Former Chief Scientific Advisor to Operation Warp Speed, and Professor Saul Faust – PI for the ongoing Johnson & Johnson Phase 3 ENSEMBLE 2 trial.

Speakers included:

Prof Saul Faust, Professor of Paediatric Immunology & Infectious Diseases, University of Southampton and University Hospital Southampton NHS Foundation Trust

Dr Paul Stoffels, M.D. Johnson & Johnson’s Vice Chairman of the Executive Committee and Chief Scientific Officer

Moncef Slaoui, Ph.D. Collaborator on the trial and Former Chief Scientific Advisor to Operation Warp Speed

This Briefing was accompanied by an SMC Roundup of Comments.